|
๐
|
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
22 auth.
R. Fleischmann,
D. M. van der Heijde,
V. Strand,
T. Atsumi,
I. McInnes,
Tsutomu Takeuchi,
Peter C Taylor,
Marguerite Bracher,
David Brooks,
John Davies,
...
Christopher Goode,
Anubha Gupta,
S. Mukherjee,
Ciara OโShea,
D. Saurigny,
L. Schifano,
Celia Shelton,
Julia E Smith,
Millie Wang,
Reena Wang,
S. Watts,
M. Weinblatt
|
3 |
2023 |
3
๐
|
|
๐
|
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)
21 auth.
P. Taylor,
M. Weinblatt,
I. McInnes,
T. Atsumi,
V. Strand,
Tsutomu Takeuchi,
Marguerite Bracher,
David Brooks,
John Davies,
Christopher Goode,
...
Anubha Gupta,
S. Mukherjee,
Ciara OโShea,
D. Saurigny,
L. Schifano,
Celia Shelton,
Julia E Smith,
Millie Wang,
Reena Wang,
S. Watts,
R. Fleischmann
|
3 |
2023 |
3
๐
|
|
๐
|
GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcฮณ receptor region
72 auth.
Y. Ishikawa,
Nao Tanaka,
Y. Asano,
M. Kodera,
Yuichiro Shirai,
M. Akahoshi,
M. Hasegawa,
T. Matsushita,
Kazuyoshi Saito,
S. Motegi,
H. Yoshifuji,
A. Yoshizaki,
T. Kohmoto,
Kae Takagi,
Akira Oka,
...
Miho Kanda,
Yoshihito Tanaka,
Yumi Ito,
K. Nakano,
H. Kasamatsu,
A. Utsunomiya,
Akiko Sekiguchi,
H. Niiro,
Masatoshi Jinnin,
K. Makino,
T. Makino,
H. Ihn,
M. Yamamoto,
C. Suzuki,
Hiroki Takahashi,
E. Nishida,
A. Morita,
Toshiyuki Yamamoto,
Manabu Fujimoto,
Y. Kondo,
D. Goto,
Takayuki Sumida,
N. Ayuzawa,
H. Yanagida,
T. Horita,
T. Atsumi,
Hirahito Endo,
Yoshihito Shima,
Atsushi Kumanogoh,
Jun Hirata,
N. Otomo,
H. Suetsugu,
Yoshinao Koike,
K. Tomizuka,
S. Yoshino,
Xiaoxi Liu,
Shuji Ito,
K. Hikino,
A. Suzuki,
Y. Momozawa,
S. Ikegawa,
Yoshiya Tanaka,
Osamu Ishikawa,
Kazuhiko Takehara,
Takeshi Torii,
Shinichi Sato,
Y. Okada,
T. Mimori,
Fumihiko Matsuda,
Koichi Matsuda,
Tiffany Amariuta,
Issei Imoto,
K. Matsuo,
Masataka Kuwana,
Yasushi Kawaguchi,
K. Ohmura,
Chikashi Terao
|
2 |
2024 |
2
๐
|
|
๐
|
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.
27 auth.
Oliver Distler,
Y. Allanore,
C. Denton,
M. Kuwana,
M. Matucci-Cerinic,
Janet E. Pope,
T. Atsumi,
R. Beฤvรกล,
L. Czirjรกk,
รric Hachulla,
Tomonori Ishii,
Osamu Ishikawa,
Sindhu R. Johnson,
E. De Langhe,
C. Stagnaro,
...
V. Riccieri,
E. Schiopu,
Richard M. Silver,
Vanessa Smith,
Virginia D Steen,
W. Stevens,
Gabriella Szรผcs,
M. Truchetet,
Melanie Wosnitza,
Kaisa Laapas,
Frank Kramer,
Dinesh Khanna
|
2 |
2023 |
2
๐
|
|
๐
|
The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysis.
14 auth.
Yoshiya Tanaka,
T. Atsumi,
Masato Okada,
T. Miyamura,
Tomonori Ishii,
Susumu Nishiyama,
Ryutaro Matsumura,
Atsushi Kawakami,
N. Hayashi,
G. Abreu,
...
Sule Yavuz,
C. Lindholm,
Hussein Al-Mossawi,
Tsutomu Takeuchi
|
2 |
2023 |
2
๐
|
